Viatris Reaches $264m EpiPen Settlement Agreement With Trial Imminent
Company Admits No Wrongdoing; Maintains ‘That It Acted Lawfully’
Viatris has reached an agreement worth a little over a quarter-of-a-billion dollars to resolve one set of antitrust claims that it unlawfully withheld generic competition to its controversial EpiPen autoinjector. The charge appeared on Viatris’ 2021 P&L, which was detailed during a company investor day.
